Knight Therapeutics | GUD - Equity Capital And Reserves


Knight Therapeutics reported CAD767.27M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acasti Pharma USD 64.89M 2.07M Dec/2025
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Avita Medical AUD -16.65M 3.76M Dec/2025
Canopy Growth CAD 697.59M 60.58M Mar/2026
Cronos Group USD 1.07B 4.99M Jun/2026
Dianthus Therapeutics USD 1.17B 29.29M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
IQVIA Holdings USD 6.17B 50M Jun/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Moderna USD 6.76B 647M Jun/2026
Omeros USD -228.68M 15.13M Jun/2025
Organigram Holdings CAD 371.81M 2.36M Mar/2026
Organon & Co USD 903M 151M Mar/2026
Revvity USD 7.18B 67.62M Mar/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Tilray USD 1.58B 39.08M Sep/2025
Viatris USD 14.26B 397.3M Jun/2026
Xeris Pharmaceuticals USD -9.73M 22.74M Jun/2026